Chemical Structure (Keppraxr 01)
Keppra Tablet, Film Coated, Extended Release
Product Images NDC 50474-598
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Keppra (NDC 50474-598). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ucb, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Keppraxr 02)
This appears to be a table or chart showing percentages of patients receiving different doses of a medication (Keppra) and a placebo. The percentages are broken down into various categories, but without additional context it is unclear what those categories represent.*
Figure 2 (Keppraxr 03)
The text seems to be an excerpt from a clinical study report, but it lacks context and information to provide a meaningful description. It mentions some percentages related to patients and treatment with a medication called KEPPRA, as well as a placebo group. However, without knowing the purpose of the study, the criteria for patient selection, the outcomes measured, and other relevant details, it is not possible to provide a useful description of the text.*
Figure 3 (Keppraxr 04)
This is a table containing the percentage of patients and the number of patients (N) in a study comparing placebo and immediate-release Keppra at a dosage of 3000 mg/day. However, without additional context or information, it is difficult to determine what is being studied or what the percentages represent.*
Figure 4 (Keppraxr 05)
Principal Display Panel (500 mg Tablet Bottle Label)
Keppra XR is a trademark of UCBS.A. or its affiliates. The drug is manufactured for UCB, Inc. in Smyrna, GA, with PT# 4001562 and NDC 50474-598-66, 60 tablets for once daily dosing. The tablets are 500mg and are extended-release. Each patient must be given the accompanying medication guide. Dispense in a tight, light-resistant container with a child-resistant closure, and see the package insert for complete dosage recommendations. Store at 25°C (77°F), but excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].*
Principal Display Panel (750 mg Tablet Bottle Label)
KEPPRA XR is a medication used for seizures, it is available in the form of extended-release tablets in doses of 750 mg. The medication comes in a bottle containing 60 tablets, NDC code 50474-599-66. The recommended dosage for KEPPRA varies and should be consulted in the package insert for complete dosage recommendations. It should be dispensed in a tight, light-resistant container with a child-resistant closure. KEPPRA XR must be prescribed by a healthcare professional and should not be taken without their advice.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
